AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15293418 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (SB) at 15 s
Number of subjects: 108
Study 15293418 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (SB) at 30 s
Number of subjects: 108
Study 15293418 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step (OS) at 5 s
Number of subjects: 108
Study 15293418 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step (OS) at 15 s
Number of subjects: 108
Study 15293418 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step (OS) at 30 s
Number of subjects: 108
Study 15293418 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Single Component (SSC) at 5 s
Number of subjects: 108
Study 15293418 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Single Component (SSC) at 15 s
Number of subjects: 108
Study 15293418 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Single Component (SSC) at 30 s
Number of subjects: 108
Study 16264046 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management programme 'Living Well with COPD(TM)'
Number of subjects: 191
Study 16264046 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 191
Study 10613429 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg capsules, two times daily for 12 weeks)
Number of subjects: 40
Study 10613429 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenedione (50 mg capsules, two times daily for 12 weeks)
Number of subjects: 40
Study 10613429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10613429 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 40
Study 10613429 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA and Androstenedione
Number of subjects: 40
Study 8528478 — intervention group
Group type: EXPERIMENTAL
Intervention: Head optimally restrained
Number of subjects: 20
Study 8528478 — intervention group
Group type: EXPERIMENTAL
Intervention: Head minimally restrained
Number of subjects: 20
Study 8528478 — intervention group
Group type: COMPARATOR
Intervention: Head optimally restrained and head minimally restrained
Number of subjects: 20
Study 1902426 — intervention group
Group type: EXPERIMENTAL
Intervention: ponalrestat
Number of subjects: 20
Study 1902426 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 7129293 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation anesthesia (ESA)
Number of subjects: 0
Study 7129293 — intervention group
Group type: COMPARATOR
Intervention: Neurolept anesthesia (NLA)
Number of subjects: 0
Study 31917835 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan 0.04 mg/kg/wk
Number of subjects: 59
Study 31917835 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan 0.08 mg/kg/wk
Number of subjects: 59
Study 31917835 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan 0.16 mg/kg/wk
Number of subjects: 59
Study 31917835 — intervention group
Group type: COMPARATOR
Intervention: Daily GH 0.034 mg/kg/d
Number of subjects: 59
Study 31449860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (Group B, 2013-2017)
Number of subjects: 338
Study 31449860 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (Group A, 2008-2012)
Number of subjects: 338
Study 29352400 — intervention group
Group type: EXPERIMENTAL
Intervention: Date SMART intervention
Number of subjects: 109
Study 29352400 — intervention group
Group type: COMPARATOR
Intervention: Knowledge‐only (KO) comparison group
Number of subjects: 109
Study 26802160 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine (nab-P + Gem)
Number of subjects: 861
Study 26802160 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine alone (Gem)
Number of subjects: 861
Study 24215801 — intervention group
Group type: EXPERIMENTAL
Intervention: 150% of baseline number of chews
Number of subjects: 45
Study 24215801 — intervention group
Group type: EXPERIMENTAL
Intervention: 200% of baseline number of chews
Number of subjects: 45
Study 24215801 — intervention group
Group type: COMPARATOR
Intervention: 100% of baseline number of chews
Number of subjects: 45
Study 24215801 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of chews
Number of subjects: 45
Study 22306585 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose plus booster on day 21
Number of subjects: 150
Study 22306585 — intervention group
Group type: COMPARATOR
Intervention: Standard dose
Number of subjects: 150
Study 19161766 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewarming to 37 degrees C (RW‐37 degrees)
Number of subjects: 490
Study 19161766 — intervention group
Group type: COMPARATOR
Intervention: Rewarming to 34 degrees C (RW‐34 degrees)
Number of subjects: 490
Study 19161766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained mild hypothermia at 34 degrees C (S‐34 degrees)
Number of subjects: 490
Study 19161766 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (S‐37 degrees)
Number of subjects: 490
Study 17206437 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity plantar flexion exercise (3.44 +/- 0.73 W per unit active muscle mass)
Number of subjects: 9
Study 16045528 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG IUS)
Number of subjects: 51
Study 16045528 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid
Number of subjects: 51
Study 12195350 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 16
Study 12195350 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapeutic vaccine trial (for 11 of the 16 subjects)
Number of subjects: 16
Study 12195350 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued therapy
Number of subjects: 16
Study 10774649 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bed nets
Number of subjects: 0
Study 10774649 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated bed nets
Number of subjects: 0
Study 8563364 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized prompting system for test ordering
Number of subjects: 0
Study 31157379 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (nutrition education and environmental dietary modification)
Number of subjects: 517
Study 31157379 — intervention group
Group type: EXPERIMENTAL
Intervention: Environment (environmental dietary modification)
Number of subjects: 517
Study 28522812 — intervention group
Group type: EXPERIMENTAL
Intervention: FELIAP (Factor ELeven Inhibitory APtamer)
Number of subjects: 89
Study 28522812 — intervention group
Group type: COMPARATOR
Intervention: SCRAPT (scrambled aptamer control)
Number of subjects: 89
Study 28522812 — intervention group
Group type: EXPERIMENTAL
Intervention: FELIAP
Number of subjects: 89
Study 25448332 — intervention group
Group type: EXPERIMENTAL
Intervention: Delafloxacin 300mg IV every 12h
Number of subjects: 0
Study 25448332 — intervention group
Group type: EXPERIMENTAL
Intervention: Delafloxacin 450mg IV every 12h
Number of subjects: 0
Study 25448332 — intervention group
Group type: COMPARATOR
Intervention: Tigecycline 100mg IV×1, followed by 50mg IV every 12h
Number of subjects: 0
Study 24153411 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week taper
Number of subjects: 70
Study 24153411 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week taper
Number of subjects: 70
Study 24153411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week taper
Number of subjects: 70
Study 20844459 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib‐MenC‐TT booster
Number of subjects: 271
Study 20844459 — intervention group
Group type: EXPERIMENTAL
Intervention: MenC‐CRM
Number of subjects: 271
Study 20844459 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 271
Study 18290565 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab induction therapy combined with Calcineurin inhibitors (CNI) and steroids
Number of subjects: 99
Study 18290565 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitors and steroids only (Control)
Number of subjects: 99
Study 15613978 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg
Number of subjects: 21
Study 15613978 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 21
Study 12453955 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1079
Study 10455633 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure inflatable mattress and cushion system (Repose)
Number of subjects: 80
Study 10455633 — intervention group
Group type: COMPARATOR
Intervention: Dynamic support mattress (Nimbus II) with alternating-pressure cushion (Alpha TranCell)
Number of subjects: 80
Study 7739947 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg orally 1 hour before imaging procedure
Number of subjects: 85
Study 7739947 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 85
Study 2287655 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive therapy
Number of subjects: 10
Study 2287655 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual supportive treatment plus brief counseling contacts
Number of subjects: 10
Study 7255511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene/paracetamol (65 mg dextropropoxyphene hydrochloride and 650 mg paracetamol)
Number of subjects: 6
Study 7255511 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (1.2 g)
Number of subjects: 6
Study 7255511 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin (1.2 g)
Number of subjects: 6
Study 7255511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31789000 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 162
Study 31789000 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 162
Study 30151994 — intervention group
Group type: EXPERIMENTAL
Intervention: V- AS group (vonoprazan 20-mg bid, amoxicillin 750-mg bid, sitafloxacin 100-mg bid for 7 days)
Number of subjects: 63
Study 30151994 — intervention group
Group type: COMPARATOR
Intervention: PPI- AS group (esomeprazole 20-mg bid, rabeprazole 10-mg bid, or lansoprazole 30-mg bid; amoxicillin 750-mg bid; sitafloxacin 100-mg bid for 7 days)
Number of subjects: 63
Study 24071772 — intervention group
Group type: EXPERIMENTAL
Intervention: GXR AM (Guanfacine Extended Release in the morning)
Number of subjects: 461
Study 24071772 — intervention group
Group type: EXPERIMENTAL
Intervention: GXR PM (Guanfacine Extended Release in the evening)
Number of subjects: 461
Study 26487300 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly survey plus tailored risk reduction messages
Number of subjects: 179
Study 26487300 — intervention group
Group type: COMPARATOR
Intervention: Monthly internet survey alone
Number of subjects: 179
Study 26487300 — intervention group
Group type: COMPARATOR
Intervention: Both intervention and control groups
Number of subjects: 179
Study 23943412 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 23943412 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 23943412 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 23943412 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22855581 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 79
Study 22855581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 22855581 — intervention group
Group type: EXPERIMENTAL
Intervention: Low IGF1R
Number of subjects: 79
Study 19412914 — intervention group
Group type: EXPERIMENTAL
Intervention: 20G needle
Number of subjects: 200
Study 19412914 — intervention group
Group type: COMPARATOR
Intervention: 22G needle
Number of subjects: 200
Study 17537539 — intervention group
Group type: EXPERIMENTAL
Intervention: Low- to moderate-intensity, short-duration physical activity (12 min walking protocol)
Number of subjects: 14
Study 17537539 — intervention group
Group type: COMPARATOR
Intervention: Glucose preload (250 ml with water)
Number of subjects: 14
Study 17537539 — intervention group
Group type: COMPARATOR
Intervention: Whey protein preload (250 ml with water)
Number of subjects: 14
Study 17537539 — intervention group
Group type: COMPARATOR
Intervention: SPLENDA Sucralose control (250 ml with water)
Number of subjects: 14
Study 17537539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation threshold (VeT)
Number of subjects: 14
Study 15752236 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary albumin concentration (UAC) measured in a spot morning urine sample
Number of subjects: 2527
Study 15752236 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-creatinine ratio (ACR) measured in a spot morning urine sample
Number of subjects: 2527
Study 12046341 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h ambulatory blood pressure monitoring
Number of subjects: 59
Study 12046341 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH assessment
Number of subjects: 59
Study 12046341 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI assessment
Number of subjects: 59
Study 9651453 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air
Number of subjects: 609
Study 9651453 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 609
Study 7842816 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase once daily
Number of subjects: 968
Study 7842816 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase twice daily
Number of subjects: 968
Study 7842816 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase
Number of subjects: 968
Study 7842816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study 2153040 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 IU of salmon calcitonin
Number of subjects: 40
Study 2153040 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU of salmon calcitonin
Number of subjects: 40
Study 2153040 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of salmon calcitonin
Number of subjects: 40
Study 2153040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 366722 — intervention group
Group type: EXPERIMENTAL
Intervention: benoxaprofen 200 mg b.d. for three weeks
Number of subjects: 0
Study 366722 — intervention group
Group type: COMPARATOR
Intervention: naproxen 250 mg b.d. for two weeks
Number of subjects: 0
Study 30063267 — intervention group
Group type: EXPERIMENTAL
Intervention: High-functioning occasional heavy drinkers
Number of subjects: 806
Study 30063267 — intervention group
Group type: EXPERIMENTAL
Intervention: High-functioning infrequent non-heavy drinkers
Number of subjects: 806
Study 30063267 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor functioning frequent heavy drinkers
Number of subjects: 806
Study 30063267 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor functioning infrequent heavy drinkers
Number of subjects: 806
Study 29479872 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-D supplementation
Number of subjects: 41
Study 29479872 — intervention group
Group type: COMPARATOR
Intervention: Low vitamin-D levels
Number of subjects: 41
Study 27439448 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6*1/*1
Number of subjects: 36
Study 27439448 — intervention group
Group type: COMPARATOR
Intervention: CYP2B6*1/*6
Number of subjects: 36
Study 27439448 — intervention group
Group type: COMPARATOR
Intervention: CYP2B6*6/*6
Number of subjects: 36
Study 27439448 — intervention group
Group type: EXPERIMENTAL
Intervention: POR rs2868177 AA homozygotes
Number of subjects: 36
Study 27439448 — intervention group
Group type: COMPARATOR
Intervention: POR rs2868177 AG heterozygotes
Number of subjects: 36
Study 27439448 — intervention group
Group type: COMPARATOR
Intervention: POR rs2868177 GG homozygotes
Number of subjects: 36
Study 27439448 — intervention group
Group type: EXPERIMENTAL
Intervention: POR rs2868177 AG heterozygotes in CYP2B6*1/*1
Number of subjects: 36
Study 27439448 — intervention group
Group type: COMPARATOR
Intervention: POR rs2868177 AA homozygotes in CYP2B6*1/*1
Number of subjects: 36
Study 27439448 — intervention group
Group type: EXPERIMENTAL
Intervention: POR rs2868177 GG homozygotes in CYP2B6*6
Number of subjects: 36
Study 27439448 — intervention group
Group type: COMPARATOR
Intervention: POR rs2868177 AA homozygotes in CYP2B6*6
Number of subjects: 36
Study 24070326 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure with Sinapsis alba seeds
Number of subjects: 49
Study 24070326 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 22373563 — intervention group
Group type: COMPARATOR
Intervention: Modified Radical Mastectomy (MRM)
Number of subjects: 868
Study 22373563 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-Conserving Therapy (BCT)
Number of subjects: 868
Study 20850556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (2mg IV infusion)
Number of subjects: 24
Study 20850556 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IV infusion)
Number of subjects: 24
Study 17438179 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream applied twice a day for 4 weeks
Number of subjects: 12
Study 17438179 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle cream) applied twice a day for 4 weeks
Number of subjects: 12
Study 16083542 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 3-12 mg/day
Number of subjects: 994
Study 16083542 — intervention group
Group type: COMPARATOR
Intervention: Donepezil 5-10 mg/day
Number of subjects: 994
Study 16083542 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 994
Study 16083542 — intervention group
Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 994
Study 12196335 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 23
Study 10337433 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine ophthalmic solution (0.1%)
Number of subjects: 0
Study 10337433 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac ophthalmic solution (0.5%)
Number of subjects: 0
Study 7586946 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate 2400 mg/day
Number of subjects: 0
Study 7586946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7586946 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate
Number of subjects: 0
Study 2180748 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (low dose)
Number of subjects: 32
Study 2180748 — intervention group
Group type: COMPARATOR
Intervention: Control (no methylprednisolone)
Number of subjects: 32
Study 7370142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.08 mg kg‐1
Number of subjects: 26
Study 7370142 — intervention group
Group type: COMPARATOR
Intervention: Metocurine 0.4 mg kg‐1
Number of subjects: 26
Study 7370142 — intervention group
Group type: COMPARATOR
Intervention: Tubocurarine 0.4 mg kg‐1
Number of subjects: 26
Study 29560806 — intervention group
Group type: EXPERIMENTAL
Intervention: Iranian pop music
Number of subjects: 64
Study 29560806 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional music
Number of subjects: 64
Study 29560806 — intervention group
Group type: EXPERIMENTAL
Intervention: Mozart's classical music
Number of subjects: 64
Study 29560806 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 64
Study 29553889 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups collectively low in testosterone
Number of subjects: 74
Study 29553889 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups collectively high in testosterone
Number of subjects: 74
Study 25867005 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) - 5 hours per week, 12 hours total training per week, 6-10 × 10-30 seconds maximal effort with 2-4 minutes rest
Number of subjects: 41
Study 25867005 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) - 1 hour of HIT, 35 km total distance per week, 12 hours total training per week
Number of subjects: 41
Study 24689367 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin derivatives during the proliferative phase
Number of subjects: 135
Study 24689367 — intervention group
Group type: COMPARATOR
Intervention: Conventional hormone replacement cycle without prostaglandin
Number of subjects: 135
Study 22816797 — intervention group
Group type: EXPERIMENTAL
Intervention: PaJR intervention with lay care guides and predictive modeling
Number of subjects: 214
Study 22816797 — intervention group
Group type: EXPERIMENTAL
Intervention: PaJR intervention with lay care guides
Number of subjects: 214
Study 22816797 — intervention group
Group type: EXPERIMENTAL
Intervention: PaJR intervention with predictive analytics
Number of subjects: 214
Study 22816797 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 214
Study 21176144 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative therapy (drotrecogin alfa at 24/30/36 μg/kg/hr for 48 to 168 hours)
Number of subjects: 557
Study 21176144 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (drotrecogin alfa at 24 μg/kg/hr infusion for 96 hours)
Number of subjects: 557
Study 18255347 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with stent placement
Number of subjects: 48
Study 18255347 — intervention group
Group type: COMPARATOR
Intervention: Biliary stents alone (control group)
Number of subjects: 48
Study 18255347 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 48
Study 16182683 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled sleep restriction with hypnotic administration in the first week
Number of subjects: 6
Study 12634619 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC D‐99 (60 mg/m2) with cyclophosphamide (600 mg/m2)
Number of subjects: 20
Study 12634619 — intervention group
Group type: COMPARATOR
Intervention: Conventional doxorubicin (60 mg/m2) with cyclophosphamide (600 mg/m2)
Number of subjects: 20
Study 10790679 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parametric analysis of covariance methods
Number of subjects: 722
Study 10790679 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional hazards regression models
Number of subjects: 722
Study 10790679 — intervention group
Group type: EXPERIMENTAL
Intervention: Product-limit estimators of cumulative survival
Number of subjects: 722